FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of immunology. Claimed is application of monoclonal antibody against human Fas ligand protein (CD95L, or Apo1L, or FasL) or its antigen-binding fragment for manufacturing medication for prevention and/or treatment of skin diseases, associated with acantholysis of keratinocytes, in particular for prevention and/or treatment of pemphigus, where antibody contains amino acid sequences CDR of 3E1 antibody or is produced by hybridoma ATCC PTA-4017.
EFFECT: application of antibody in accordance with invention or its antigen-binding fragment provides more effective prevention of desmoglein (dsg3) cleavage in comparison with application of other antibodies.
11 cl, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATIONS FOR TREATING PEMPHIGUS CONTAINING ANTIBODIES TO Fas-LIGAND | 2008 |
|
RU2558260C2 |
| INHIBITORS OF CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS | 2013 |
|
RU2652348C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| NEW ANTIBODIES AGAINST HEPATITIS B VIRUS AND APPLICATION THEREOF | 2020 |
|
RU2814471C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2775944C2 |
